Acquisition of APIRx
For personal use only
OraxiMaxTM Periodontal Disease and
Gingivitis (Toothpaste and Mouthwash)
Problem
Up to 50% of adults suffer from moderate to
severe periodontitis and/or gingivitis. Heretofore,
periodontal disease treatment has been limited
to professional dental cleaning and the use
of systemic antibiotics.
Solution
OraxiMax Toothpaste and Mouthwash, backed by
fully granted IP protection, provides for disruption
of dental plaque formation, therefore preventing
gingivitis and periodontitis. Due to its proprietary
formulation the local availability of APIs are
increased while systemic absorption is kept
to minimum.
Competitive Advantage
Currently no approved similar products on the
market. Clinical Stage CE/510(k). Bioavailability
data completed and very encouraging.
To be registered as a medical device (shorter
approval pathway).
Incannex
Patents
Granted: Oral care compositions compromising
cannabinoids (CBD) and Cannabigerol (CBG).
Efficacy/Results
1) CBD / Cannabigerol (CBG) proven effective
in reducing bacterial load in dental plaque.
2) CBG effective against multi-drug-resistant flora,
e.g. MRSA.
3) Due to its proprietary formulation the
Cannabinoid APIs are increased locally while
systemic absorption is kept to a minimum.
4.) The Toothpaste and Mouthwash shows a Log
CFU reduction of 1,11 resp. 0,29 in comparison
with 0,07 of the placebo.
Benefits of CBD include:
Reduces inflammation that can
lead to gum diseases.
Attacks bacteria associated with tooth decay.
Fights bad breath.
Relieves sensitivity.
Reduces risk of cavities.
Encourages tooth remineralizing.
Restores pH balance.
Addressable Market (a)
Lead Assets
US$ 42B 46%
Associated Total Direct
Healthcare Costs
(U.S., Europe) in '21
Next Steps:
Coordination of phase 2 clinical trial followed by
commercial preparations for product launch.
Prevalence in U.S. of
Adult Population
a) Frost & Sullivan Market Report as commissioned by APIRX, Oct. 2021
Shareholder Presentation
20View entire presentation